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Abstract- High-dose extended-interval dosage (HDED) regimen of aminoglycosides is now considered as the 
standard dosage strategy in sepsis. Although safety and efficacy of this dosing regimen is well studied,  but new 
experiments show increased the risk of resistance development associated with %T>MIC less than 60% of the 
dosing interval following extended interval dosing. Moreover, limited information is available about safety of 
more frequent administration of high dose aminoglycosides. Authors studied nephrotoxicity following seven 
days’ exposure to more frequent administration of higher doses of amikacin comparing with HDED regimen. In 
addition to Serum Creatinine (SrCr) and estimated glomerular filtration rate (eGFR), nephrotoxicity was studied 
with Neutrophil gelatinase-associated lipocalin (NGAL), a direct marker of tubular injury. A total of 40 patients 
with sepsis were quasi-randomized in two groups. Seven days’ course of treatment with a moderate dose of 
amikacin (12.5 mg/Kg) was administered every 12 hours, known as the moderate-dose non-liberal-interval 
dosage  (MDNLD)  regimen compared with the high-dose extended-interval dosage (HDED) regimen (25mg/Kg 
every 24 hours). The pharmacokinetic/pharmacodynamic (PK/PD) goal of the MDNLD regimen was the 
Cmax>40 and the %T>MIC more than 60% during the PK/PD goal for the HDED regimen was the Cmax>60. The 
eGFR change from the baseline was the primary outcome of the study with a minimum clinical significance of 
20ml/min (estimated SD of 20, Power>90%, P<0.05). No difference was observed between groups for the 
values of eGFR change and the SrCr percent change from the baseline (P=0.359 and P=0.114, respectively). 
Frequency of acute kidney injury also did not differ between groups (P=0.342). Serum NGAL level values’ 
change from the baseline was more in the HDED regimen in comparison with the MDNLD regimen at third day 
and fifth day of the treatment (P=0.001 and P =0.002, respectively).  This indicates a safer pattern of moderate 
doses with more frequent administration of amikacin at the tubular injury level. Higher doses of amikacin could 
be safely administered to achieve PK/PD goal of Cmax>40 and %T>MIC more than 60% of the dosing interval. 
This dosing regimen would be considered as an alternative to minimize the resistance development associated 
with the extended-interval dosing in septic patients with multi-drug resistant gram-negative organisms. 
© 2014 Tehran University of Medical Sciences. All rights reserved.  
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In recent years, aminoglycosides have become the 
mainstay of combination antimicrobial chemotherapy 
against multi-drug resistant gram negatives. Many 
guidelines consider aminoglycosides and specially 
amikacin to be one of the best choices of treatment in 
sepsis and septic shock in critically ill patients (1,2). 
However, increase in minimum inhibitory concentration 
(MIC) of some of these pathogens namely Acinetobacter 
baumannii has raised concerns about the future of sepsis 
control (3-6). The MIC breakpoints for amikacin against 
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sensitive A. baumannii is now considered as high as 8 
mg/lit (7). 
In conventional dosing regimens, most experts use 
moderate doses of amikacin (15-20 mg/Kg) with the 
pharmacokinetic goal of Cmax 40-60 mg/lit every 24 
hours and low doses of amikacin (7.5-10 mg/Kg) with 
the pharmacokinetic goal of Cmax 20-30 mg/lit every 12 
hours as the two standard regimens (8). 
Concerning  recent amikacin MIC breakpoints for A. 
baumannii and growing evidence for the impact of 
reaching Cmax: MIC of at least eight to achieve sufficient 
effects (9,10), many practitioners have settled on the 
high dose amikacin in sepsis control to reach the Cmax 
goal of 60-80 mg/lit (estimated dose of 25mg/Kg) (5). 
Because of  concerns about the nephrotoxicity of higher 
doses, most of these regimens are designed to provide 
highest levels of Cmax while maintaining the Cmin and 
AUC values at lower levels by means of the lowest 
theoretical effective frequency of every 24 hours (11). 
Considering the post antibiotic effect (PAE) of 
aminoglycosides, these regimens known as the high-
dose extended-interval dosage (HDED) regimens are 
believed to be more effective than conventional dosing 
regimens. The PAE of aminoglycosides is reported to be 
0.5 to 8 hours after the drug concentration drops under 
MIC levels (11). Many studies have confirmed the 
efficacy of HDED amikacin regimens (>25mg/Kg every 
24 hours) in settings with a high prevalence of high-
resistant pathogens (5). However, it is estimated that up 
to 50% of the patients may experience concentrations 
lower than MIC for more than 10 hours within dosing 
intervals (%T>MIC less than 60% of the intervals) (12).  
Although the body of the literature supports the Cmax: 
MIC as the major pharmacokinetic/pharmacodynamic 
(PK/PD) goal to prevent aminoglycoside resistance, one 
should not ignore the importance of keeping the %T>MIC 
longer than 60% of the intervals as another PK/PD goal. 
Aminoglycosides are short half-life agents (2-3 hours) 
with limited PAE (0.5-8 hours) duration; Therefore, 
probability of developing drug resistance that is 
associated with extended-interval dosing might be 
challenging (13). Despite satisfactory results regarding 
the HDED amikacin regimen’s efficacy against high-
resistant pathogens, it should not be interpreted as the 
capability to prevent antibiotic resistance. Information 
about drug resistance development associated with the 
HDED regimens is not sufficient in clinical practice. 
Zazo et al., have described the association of the 
extended interval regimens with drug resistance 
development and discussed the need for more frequent 
administration of amikacin and other aminoglycosides to 
prevent it (12). In the lack of data about the 
nephrotoxicity potential of more frequent dosing of the 
high dose aminoglycosides, it would be unsafe to apply 
these recommendations in clinical practice without 
further investigation. 
The present study investigates nephrotoxicity of a 
new amikacin dosing regimen, moderate-dose non-
liberal-interval dosage (MDNLD), in comparison with 
standard HDED amikacin regimen (25mg/kg every 24 
hours) in ICU patients with sepsis. Neutrophil 
gelatinase-associated lipocalin (NGAL) as a direct 
marker of tubular injury is used in this study in addition 
to other indirect markers including serum creatinine 
(SrCr) and estimated glomerular filtrations rate (eGFR). 
Serum NGAL could predict kidney injury events 24-48 
hours beyond the seven days’ course of follow-up with 
an acceptable sensitivity (14). 
The new MDNLD amikacin regimen provides more 
frequent (every 12 hours) dosing to preserve the %T>MIC 
longer than 60% of the dosing intervals while enjoying 
the lower range of acceptable Cmax value of 30-50 mg/lit 
with moderate doses of amikacin (12.5 mg/Kg). 
  
Materials and Methods 
 
Trial design 
This trial was a quasi-randomized clinical trial 
(quasi-RCT) with parallel intervention and historical 
control groups. These study groups were subgroups of a 
previous trial, conducted to compare the nephrotoxicity 
of the high dose once daily, the moderate dose once 
daily and the moderate dose twice daily of amikacin 
regimens. Because of several limitations, the authors 
decided not to investigate all three groups 
simultaneously. Comparison of a high dose and the 
moderate dose once daily regimens was considered as 
the first phase of the investigation (2009-2011). In this 
phase of the trial, authors compared the nephrotoxicity 
of the moderate dose twice daily of amikacin with the 
historical control group of the high dose once daily of 
amikacin. The reasons for ICU admission of the 
patients, patient-to-nurse ratio, ICU equipment, pattern 
of antibiotic resistance and therapeutic protocols have 




Patients admitted to the general ICU ward of Sina 
Hospital affiliated to Tehran University of Medical 
Sciences (TUMS), Tehran, Iran from August 2011 to 
March 2013 were screened for the study eligibility 
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during ICU stay. Inclusion in the study required the 
patient to be younger than 65 years with no renal 
impairment stage three and less (defined as eGFR < 60 
ml/min estimated with Cockcroft-Gault equation) and to 
have sepsis indicating empiric combination antibiotic 
therapy including amikacin against gram negative 
pathogens.  
Patients with the following conditions were excluded 
from the study: Acute renal injury development 
according to RIFLE criteria in the first 72 hours of 
inclusion, a moribund condition at the baseline, major 
cardiac, pulmonary, hepatic or hematologic disorders, 
neutropenia, history of recent antineoplastic or 
immunosuppressive chemotherapy, neuromuscular 
diseases, pregnancy, extreme body weights (BMI>35 or 
<18.5), ages below 18 years old and amikacin 
discontinuation or death before the fifth day of the 
treatment. Informed consent was obtained either from 
the patients or first-degree relatives. The study was 
conducted according to the declaration of Helsinki 
regarding study the human subjects. 
 
Interventions 
Sepsis workup is performed for every patient at the 
baseline and all relative routine critical care laboratory, 
and clinical monitoring parameters including serum 
creatinine, hemodynamic parameters and SOFA score 
(an index of severity of illness) are followed and 
documented by bedside daily visits. 
The amikacin dose contents in this study were 
categorized by the extent of amikacin dose to achieve a 
specific Cmax goal, calculated with population 
pharmacokinetic estimation. Doses with the Cmax goal of 
less than 30 mg/lit are suggested as low dose amikacin 
(dosing range of 5-10 mg/Kg), doses with the Cmax goal 
of 40-60 mg/lit are suggested as moderate dose amikacin 
(dosing range of 10-15 mg/Kg) and doses with the Cmax 
goal of more than 60 mg/lit are considered as high dose 
amikacin (dosing range of 20-25 mg/Kg). 
In this study, nephrotoxicity of a 7 days treatment 
course with moderate doses of amikacin (dose of 12.5 
mg/Kg) every 12 hours, known as the moderate-dose 
non-liberal-interval dosage (MDNLD) regimen was 
compared with high doses amikacin (dose of 20 
mg/Kg) every 24 hours, known as the high-dose 
extended-interval dosage (HDED) regimen as the 
standard of care for sepsis antibiotic therapy. All 
dosing calculations were based on patients adjusted 
body weight (ABW). The moderate dose amikacin 
used in this study was estimated to reach a calculated 
Cmax goal of >40 mg/lit and %T>MIC more than 60% of 
the dosing interval, while keeping AUC (calculated by 




Serum creatinine and eGFR calculated by Cockcroft-
Gault equation were used as the indirect index of 
nephrotoxicity and tubular injury. These indices are 
readily available in the daily practice setting and are 
feasible for sufficient response to kidney damage.  
Serum neutrophil gelatinase-associated lipocalin 
(sNGAL) was used as a more specific marker of tubular 
insult with a good sensitivity to predict early acute 
kidney injury (14,15). Considering inaccessibility to this 
marker in clinical setting, sNGAL was measured at the 
end of the study of all cases with serum specimens 
collected at first, third, fifth and seventh days of the 
study. 
Primary outcome of the study was the value of decline 
in eGFR from the baseline. The secondary outcomes were 
number of patients developing AKI and the difference of 
sNGAL concentrations compared with the baseline value. 
To measure the sNGAL concentrations, 5 ml venous 
blood samples were taken from a central catheter at 
baseline (sNGAL1) fallowed by third day (sNGAL3), 
the fifth day (sNGAL5) and the seventh day (sNGAL7) 
thereafter. Plasma was separated after centrifugation at 
4500 rpm for 15 minutes. Samples were stored at −80°C 
until the time of analysis.  
 
Sample size 
With a total sample size of 40 patients, the power of 
the study was 94% to detect a difference of at least 20 
ml/min from the baseline between the treatments when 
applying a two sided t-test at the level of 5%. The 
minimum clinically important difference of eGFR decline 
(20 ml/min) was assumed based on similar studies (16). 
 
Sampling and blinding of patients  
All patients with eligibility criteria allocated to the 
intervention group. Patients were blinded to antibiotic 
regimen during the experiment. After completion of the 
study, sex, age and critical illness severity (APACHE II 




All the analyses were performed using SPSS 
statistical package, version 20 for windows. Fisher's 
Exact Test was used to compare the proportions in 2×2 
tables. All variables were tested for normality of 
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distribution with Kolmogorov-Smirnov test. Student’s t-
test and Mann– Whitney U test were used to examine 
the differences between groups at the each time point for 
parametric and nonparametric variables, respectively. To 
assess the value of change from the baseline between 
groups, values were reproduced with subtraction or 
percentage change calculation and then independent 
sample t-test or Mann-Whitney U test between groups 
were used (depending on the nature of the variable’s 
distribution). The significance of the difference between 
sNGAL concentrations within groups was tested with 
Freidman’s 2-way ANOVA by ranks.  
To specify the time points which are significantly 
different from the other levels, Wilcoxon Signed Rank 
test was used to compare all time points in a pairwise 





Participant flow and recruitment 
A total of 24 patients were assigned to the 
intervention group where 4 cases excluded based on 
the exclusion criteria. The excluded participants 
included one patient with AKI within first 72 hours, 
one death and two patients with antibiotic 
discontinuation before 5th day of the treatment. At the 
end of the study, a total of 40 patients were analyzed 
for the primary outcome. Patients recruited to the study 
from August 2011 to March 2013 with the intention to 
treatment goal of 7 days. 
 
Baseline data 
Table 1 describes baseline characteristics of the study 
population. The difference between study groups was not 
significant regarding age, gender, ideal body weight 
(IBW), APACHE II score, SOFA score, serum creatinine 
(SrCr) and estimated glomerular filtration rate (eGFR) at 
the baseline.  
The mean administered dose of amikacin (mg/dose) 
was 755 ± 5 and 1493 ± 31 in MDNLD and HDED 
regimen, respectively. Considering more frequent dosing 
in MDNLD regimen, the median dosing rate (total daily 
dose) based on patient’s adjusted body weight 
(mg/Kg/day) did not differ significantly between the 
groups with a median of 21.8 ± 0.5 and 22.4 ± 
0.4,respectively (P.value=0.735).  
 
 
Table 1. Comparison between baseline characteristics of  
intervention and control groups 
Frequencies HDED Amikacin  Regimen (N=20) 




Male gender 14(70%) 16(80%) 0.716 a 
Measures Mean ± S.E Mean ± S.E Sig. (2-tailed) 
Age (year) 44.0±3.2 40.5±3.0 0.285b 
APACHE II at the baseline 12.1±1.3 12.8±1.0 0.674b 
SOFA at the baseline 6.15±0.52 6.00±0.48 0.833b 
Pretreatment SrCr (mg/dL) 0.77±0.04 0.78±0.04 0.863b 
Pretreatment GFR (ml/min) 114±6 120±8 0.543b 
sNGAL1 (ng/ml) 97.22±11.28¥ 111.96±12.63¥ 0.344 c 
IBW (Kg) 65.0±1.6¥ 68.0±1.6¥ 0.786 c 
Dosing Rate Per Kg of ABW 
(mg/Kg/day) 22.4±0.4
¥ 21.8±0.5¥ 0.735 c 
a Tested with Fisher's Exact Test 
b Tested with Independent sample t-test 
c Tested with Mann-Whitney U test 
¥ Values are mentioned as median ± S.E 
Abbreviations: HDED: high-dose extended-interval dosage; MDNLD: moderate-dose non-liberal-
interval dosage; sNGAL1: serum NGAL level at 1st day; IBW: ideal body weight; ABW: adjusted body 
weight; S.E: standard error 
 
Outcomes and estimation 
Table 2 describes the primary and secondary 
outcomes of the present study. The difference values of 
eGFR before and after the treatment as the primary 
outcome were not statistically significant between 
groups (P=0.359, mean the difference= -7.5, 
Power=0.65). Other secondary outcomes tested include 
difference of AKI occurrence during the study between 
groups, change in SOFA score and percentage change of 
serum creatinine from the baseline after the treatment 
that were not statistically significant (P=0.342, P=0.949 
and P=0.114 respectively). 
The values of sNGAL concentrations in four 
consecutive time-points are illustrated in figure 1 for 
each group. The changes of sNGAL concentrations 
within groups were only significant in HDED group 
F. Najmeddin, et al. 
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(P=0.044). Comparison between the sNGAL levels 
within HDED group showed statistical significance 
between sNGAL3 and sNGAL1 levels (P=0.048 after 
Bonferroni correction n=6) (Figure 1). 
 
 
Table 2. Measurements of outcomes  
frequencies HDED Amikacin Regimen (N=20) 




Frequency of AKI  2(10%) 1(5%) 0.342a 
measures Mean ± S.E Mean ± S.E Sig.  (2-tailed) 
Value of SOFA score difference 1.10  ± 2.84 1.05 ± 1.93 0.949 b 
Percentage change of SrCr 12.7 ± 7.53¥ 2.5 ± 10.97¥ 0.114 c 
value of GFR difference -11.75 ± 24.09 -4.25 ± 26.91 0.359 b 
a Tested with Fisher's Exact Test 
b Tested with Independent sample t-test 
c Tested with Mann-Whitney U test 
¥ Values are mentioned as median ± S.E 
Abbreviations: HDED: high-dose extended-interval dosage; MDNLD: moderate-dose non-liberal-
interval dosage; S.E: standard error 
 
The difference value of sNGAL concentration from 
the baseline in each time point was compared between 
groups as another outcome. Table 3 compares the value 
of change in sNGAL levels from the baseline in each 
time point in both groups. The difference was 
statistically significant at third day and fifth day between 
groups (P=0.001 and P=0.002, respectively). 
 
 
Figure 1. Values of sNGAL levels within 7 days of study (median and quartiles);*: statistical significance with P.value<0.05 
 
Table 3. Difference values of sNGAL from the baseline 
 HDED Amikacin  Regimen (N=20) 




 Median  (Lower band, Upper band) 
Median  
(Lower band, Upper band) P value 
sNGAL3  diff 27.33 (2.38,63.45) -11.43(-38.66,8.19) 0.001 
sNGAL5 diff 26.55(-8.12,54.75) -18.45(-75.67,3.83) 0.002 
sNGAL7 diff 15.14(-19.95,63.00) 2.25(-53.21,32.96) 0.204 
sNGAL3 diff: Change of serum NGAL level at third day from the baseline; sNGAL5 diff: change of 
serum NGAL level at fifth day from the baseline; sNGAL7 diff: the change of serum NGAL level at 




Current study results show tubular exposure to the 
Moderate-dose non-liberal-interval dosage (MDNLD) 
regimen of amikacin does not seem to be more 
nephrotoxic than the high-dose extended-interval dosage 
(HDLD). This comparison was made by both indirect 
indices of the kidney injury (serum creatinine and 
eGFR) and NGAL as a direct marker of tubular insult.  
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Large amounts of studies are in the literature which 
have compared the nephrotoxicity of conventional low 
doses with more frequent amikacin dosing regimen 
(Cmax goal of 20-30 mg/lit every 12 hours) with 
moderate-high doses with extended intervals (Cmax goal 
40-60 mg/lit every 24 hours) in various setting and 
subpopulations. Controversial results of these studies 
indicate a small trend toward the more nephrotoxic 
pattern of more frequent regimens, although it has been 
challenged with numerous meta-analysis studies 
(8,17,18).  
MDNLD regimen of amikacin may not be 
considered equivalent to conventional regimens, because 
its goal is to reach desirable Cmax values (>40 mg/lit) of 
each administered dose while keeping the %T>MIC higher 
than 60% of the dosing intervals. Considering present 
study as the first one which investigated the 
nephrotoxicity of  higher doses of amikacin during more 
frequent intervals, authors used moderate doses (with 
estimated Cmax >40 mg/lit) instead of high doses (goal 
Cmax of 60-80 mg/lit) to prevent AUC and Cmin to reach 
inconvenient values. 
One of the limitations of this study is an application 
of moderate doses of amikacin that may not reach the 
PK/PD goal of Cmax: MIC >8. However, authors were 
not concerned about insufficient efficacy for this 
regimen because of comparable AUC: MIC values with 
the MDNLD and HDED regimens. Tam et al., reported 
that in spite of guideline’s emphasis on keeping Cmax: 
MIC value as high as possible, AUC: MIC in more 
frequent dosing regimens of aminoglycosides may still 
be as a reliable PK/PD goal (19). 
The seven days treatment course of the study may also 
be noted as a relatively short tubular exposure to 
aminoglycosides while treatments beyond 10 days are 
associated with a higher incidence of nephrotoxicity. 
Using NGAL in this study would be considered as a 
modality to provide the prediction of renal failure 
occurrence (with the cut-off value of 300ng/ml) in next 
24-48 hours after the follow-up (total of 8-9 days) (14, 
15). 
Quasi-randomization of this trial is another 
limitation. However, the equivalent characteristics of the 
patients at the baseline would minimize any external 
source of error to affect the results. 
In our current situation with increasing prevalence of 
extensively drug-resistant (XDR) and pan drug-
resistant (PDR) pathogens (5), risk of drug resistance 
development seems to be serious. The authors 
recommend that future studies could evaluate potential 
of moderate-dose non-liberal-interval dosage (MDNLD) 
regimen of amikacin to prevent drug resistance 
development with pharmacokinetic/pharmacodynamic 
techniques.  
In addition, Pharmacokinetic changes of the patients’ 
parameters during the acute phase of sepsis (first 48-72 
hours) (20) may indicate even higher doses of amikacin 
with more frequencies as the early goal therapy (15-
25mg/Kg every 8-12 hours). However, individualization 
of therapy would be necessary after the acute phase with 
the goal of Cmax: MIC>8 and %T>MIC more than 60% of 
the dosing intervals. Regarding these recommendations, 
investigating the safety of high-dose non-liberal-interval 
dosage (HDNLD) regimens of amikacin (Cmax 60-80 
every 12 hours) in early stages of sepsis could be an 
attractive aria of interest. 
In addition, it must be considered that antibiotic 
therapy in sepsis is a single part of the care plan. In spit 
of using combination antibiotic therapy with optimal 
dosing regimen design, sepsis would be a hard situation 
to handle; while the outcome of the treatment depends 
on other modalities including sufficient hemodynamic 
and nutrition support beside appropriate antimicrobial 
chemotherapy. 
In the current study, authors have introduced 
moderate-dose non-liberal-interval dosage (MDNLD) 
regimen of amikacin to the clinical practice of sepsis 
management with comparative nephrotoxicity pattern to 
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